Literature DB >> 31258458

RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition.

Lauren Rackley1, Jaimie Marie Stewart2, Jacqueline Salotti3, Andrey Krokhotin4, Ankit Shah5, Justin R Halman1, Ridhima Juneja1, Jaclyn Smollett1, Lauren Lee1, Kyle Roark1, Mathias Viard6, Mubin Tarannum1, Juan Vivero-Escoto1, Peter F Johnson3, Marina A Dobrovolskaia5, Nikolay V Dokholyan4, Elisa Franco7, Kirill A Afonin1.   

Abstract

RNA is a versatile biomaterial that can be used to engineer nanoassemblies for personalized treatment of various diseases. Despite promising advancements, the design of RNA nanoassemblies with minimal recognition by the immune system remains a major challenge. Here, an approach is reported to engineer RNA fibrous structures to operate as a customizable platform for efficient coordination of siRNAs and for maintaining low immunostimulation. Functional RNA fibers are studied in silico and their formation is confirmed by various experimental techniques and visualized by atomic force microscopy (AFM). It is demonstrated that the RNA fibers offer multiple advantages among which are: i) programmability and modular design that allow for simultaneous controlled delivery of multiple siRNAs and fluorophores, ii) reduced immunostimulation when compared to other programmable RNA nanoassemblies, and iii) simple production protocol for endotoxin-free fibers with the option of their cotranscriptional assembly. Furthermore, it is shown that functional RNA fibers can be efficiently delivered with various organic and inorganic carriers while retaining their structural integrity in cells. Specific gene silencing triggered by RNA fibers is assessed in human breast cancer and melanoma cell lines, with the confirmed ability of functional fibers to selectively target single nucleotide mutations.

Entities:  

Keywords:  RNA interference; RNA nanotechnology; endotoxin-free fibers; immunology; therapeutic nucleic acids

Year:  2018        PMID: 31258458      PMCID: PMC6599627          DOI: 10.1002/adfm.201805959

Source DB:  PubMed          Journal:  Adv Funct Mater        ISSN: 1616-301X            Impact factor:   18.808


  21 in total

Review 1.  Innate immune responses triggered by nucleic acids inspire the design of immunomodulatory nucleic acid nanoparticles (NANPs).

Authors:  Morgan Chandler; Morgan Brittany Johnson; Martin Panigaj; Kirill A Afonin
Journal:  Curr Opin Biotechnol       Date:  2019-11-25       Impact factor: 9.740

2.  Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles.

Authors:  Marina A Dobrovolskaia; Kirill A Afonin
Journal:  Nat Protoc       Date:  2020-10-23       Impact factor: 13.491

3.  Challenges to optimizing RNA nanostructures for large scale production and controlled therapeutic properties.

Authors:  Morgan Chandler; Martin Panigaj; Lewis A Rolband; Kirill A Afonin
Journal:  Nanomedicine (Lond)       Date:  2020-05-26       Impact factor: 5.307

4.  Branched kissing loops for the construction of diverse RNA homooligomeric nanostructures.

Authors:  Di Liu; Cody W Geary; Gang Chen; Yaming Shao; Mo Li; Chengde Mao; Ebbe S Andersen; Joseph A Piccirilli; Paul W K Rothemund; Yossi Weizmann
Journal:  Nat Chem       Date:  2020-01-20       Impact factor: 24.427

5.  Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures.

Authors:  Allison N Tran; Morgan Chandler; Justin Halman; Damian Beasock; Adam Fessler; Riley Q McKeough; Phuong Anh Lam; Daniel P Furr; Jian Wang; Edward Cedrone; Marina A Dobrovolskaia; Nikolay V Dokholyan; Susan R Trammell; Kirill A Afonin
Journal:  Small       Date:  2022-02-06       Impact factor: 13.281

Review 6.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

7.  Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.

Authors:  Ridhima Juneja; Hemapriyadarshini Vadarevu; Justin Halman; Mubin Tarannum; Lauren Rackley; Jacob Dobbs; Jose Marquez; Morgan Chandler; Kirill Afonin; Juan L Vivero-Escoto
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-18       Impact factor: 9.229

Review 8.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881

9.  A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution.

Authors:  Justin R Halman; Ki-Taek Kim; So-Jung Gwak; Richard Pace; M Brittany Johnson; Morgan R Chandler; Lauren Rackley; Mathias Viard; Ian Marriott; Jeoung Soo Lee; Kirill A Afonin
Journal:  Nanomedicine       Date:  2019-10-25       Impact factor: 5.307

Review 10.  Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).

Authors:  Weina Ke; Kirill A Afonin
Journal:  Adv Drug Deliv Rev       Date:  2021-06-16       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.